Abstract
The objective of this study was to evaluate radiolabeled DOTA-SP90 as a radiotracer for breast cancer. The in vitro competition assay showed that radiolabeled DOTA-SP90 had significant binding affinity to BT-483 cancer cells. Biodistribution, nanoSPECT/CT and nanoPET/CT imaging results indicated that radiolabeled DOTA-SP90 can accumulate in tumors. In addition, radiolabeled DOTA-SP90 peptides can also detect metastatic tumors. Therefore, radiolabeled SP90 peptide may provide the potential capability as diagnostic agent for breast cancer patients.
Keywords:
BT-483; DOTA-SP90; nanoPET/CT; nanoSPECT/CT.
Copyright © 2020 Elsevier Ltd. All rights reserved.
MeSH terms
-
Animals
-
Breast Neoplasms / diagnosis*
-
Breast Neoplasms / metabolism
-
Cell Line, Tumor
-
Female
-
Gallium Radioisotopes / pharmacokinetics*
-
Heterocyclic Compounds, 1-Ring / metabolism
-
Humans
-
Indium Radioisotopes / pharmacokinetics*
-
Mice
-
Mice, Inbred NOD
-
Mice, SCID
-
Multimodal Imaging
-
Oligopeptides / chemistry
-
Oligopeptides / pharmacokinetics*
-
Radiopharmaceuticals / chemistry
-
Radiopharmaceuticals / pharmacokinetics*
-
Tissue Distribution
-
Xenograft Model Antitumor Assays
Substances
-
Gallium Radioisotopes
-
Heterocyclic Compounds, 1-Ring
-
Indium Radioisotopes
-
Oligopeptides
-
Radiopharmaceuticals
-
SP90 peptide
-
1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid